Related Experiment Video

Updated: Sep 2, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K

Heterogeneity in RAS mutations: One size does not fit all

Nancy E Sealover1, Robert L Kortum1

  • 1Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

Science Signaling
|August 9, 2022
PubMed

Insights

RAS mutations drive 20% of cancers, but treatment is difficult due to varied mutant behaviors. This study reveals that specific KRAS Q61 substitutions significantly alter mutant KRAS activity and cancer-causing potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • RAS proteins are key regulators of cell signaling, and mutations in RAS genes are common drivers of cancer.
  • Despite the prevalence of RAS mutations, particularly in KRAS, developing targeted therapies has been challenging due to the diverse biological consequences of different RAS variants.
  • Understanding the heterogeneity of RAS mutant functions is crucial for advancing cancer treatment strategies.

Purpose of the Study:

  • To investigate the impact of specific amino acid substitutions within the KRAS Q61 mutation on its biological activity.
  • To determine how these substitutions influence the oncogenic potential of mutant KRAS.
  • To elucidate the molecular mechanisms underlying the functional heterogeneity of KRAS mutants.

Main Methods:

  • Utilizing molecular biology techniques to generate specific KRAS Q61 mutant variants.
  • Employing cell-based assays to assess the signaling activity and cellular transformation potential of these mutants.
  • Analyzing the biochemical properties and protein interactions of different KRAS Q61 mutants.

Main Results:

  • Demonstrated substantial variation in biological activity among different KRAS Q61 substitution mutants.
  • Identified specific substitutions that significantly enhance or diminish mutant KRAS oncogenicity.
  • Characterized distinct signaling profiles associated with different KRAS Q61 mutant forms.

Conclusions:

  • The specific amino acid substitution in KRAS Q61 mutants critically dictates their biologic activity and oncogenic function.
  • This heterogeneity presents a significant challenge for developing broadly effective KRAS-targeted therapies.
  • Further research into the precise mechanisms of RAS mutant variants is essential for personalized cancer medicine.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.5K